Mario Gasparri

Dr. Mario Gasparri


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2010 in European Journal of Trauma and Emergency Surgery
Verified
Journal Article
Closed access
PDF file
MGMario Gasparri
Mario Gasparri
WTW. B. Tisol
W. B. Tisol
GHG. B. Haasler
G. B. Haasler

1 April 2004 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
MGMario Gasparri
Mario Gasparri
ANAlfred C Nicolosi
Alfred C Nicolosi
GAG.HOssein Almassi
G.HOssein Almassi

1 February 2012 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
MGMario Gasparri
Mario Gasparri
WTWilliam B. Tisol
William B. Tisol
SMSaqib Masroor
Saqib Masroor

28 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
TMThomas Matoska
Thomas Matoska
Anjishnu BanerjeeAnjishnu Banerjee
Anjishnu Banerjee
ASAditya Shreenivas
Aditya Shreenivas
LJLauren Jurkowski
Lauren Jurkowski
MSMonica E Shukla
Monica E Shukla
LPLindsay Puckett
Lindsay Puckett
Background: The study of oligometastatic esophageal cancer (EC) is relatively new. Preliminary data suggests that more aggressive treatment regimens in select patients may improve survival rates in oligometastatic EC. However, the consensus recommends palliative treatment. We hypothesized that oligometastatic esophageal cancer patients treated with a definitive approach (chemoradiotherapy [CRT]) would have improved overall survival (OS) compared to those treated with a purely palliative intent and historical controls. Methods: Patients diagnosed with synchronous oligometastatic (any histology, ≤5 metastatic foci) esophageal cancer treated in a single academic hospital were retrospectively analyzed and divided into definitive and palliative treatment groups. Definitive CRT was defined as radiation therapy to the primary site with ≥40 Gy and ≥2 cycles of chemotherapy. Results: Of 78 Stage IVB (AJCC 8th ed.) patients, 36 met the pre-specified oligometastatic definition. Of these, 19 received definitive CRT, and 17 received palliative treatment. With a median follow-up of 16.5 months (Range: 2.3–95.0 months), median OS for definitive CRT and palliative groups were 90.2 and 8.1 months (p < 0.01), translating into 5-year OS of 50.5% (95%CI: 32.0–79.8%) vs. 7.5% (95%CI: 1.7–48.9%), respectively. Conclusions: Oligometastatic EC patients treated with definitive CRT benefited from that approach with survival rates (50.5%) that vastly exceeded historical standards of 5% at 5 years for metastatic EC. Oligometastatic EC patients treated with definitive CRT had significantly improved OS compared to those treated with palliative-only intent within our cohort. Notably, definitively treated patients were generally younger and with better performance status versus those palliatively treated. Further prospective evaluation of definitive CRT for oligometastatic EC is warranted.

9 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
TMThomas Matoska
Thomas Matoska
AMAbdullah A. Memon
Abdullah A. Memon
LALou-Anne Acevedo-Moreno
Lou-Anne Acevedo-Moreno
CBCalista Bulacan
Calista Bulacan
LRLisa Rein
Lisa Rein
LPLindsay Puckett
Lindsay Puckett
Background/objectives: Improvements in esophageal adenocarcinoma (EAC) treatment have reduced mortality. While chemoradiation before surgery was previously a standard of care, updated guidelines recommend peri-operative chemotherapy without chemoradiation. Continued investigation into optimal non-operative treatment paradigms for patients who defer surgery or are not candidates for surgery and certain chemotherapy regimens is needed. The impact of induction chemotherapy prior to chemoradiation on survival and surgical outcomes remains unclear. This study assessed survival and surgical outcomes in a real-world cohort of EAC patients receiving induction chemotherapy before chemoradiation. Methods: This single-institution, IRB-approved, retrospective cohort study included patients with newly diagnosed stage II-IVb (oligometastatic for IVb) EAC who received definitive chemoradiation (radiation ≥ 40 Gy and two cycles of chemotherapy) +/− esophagectomy from 2007 to 2022. Patients receiving induction chemotherapy were compared to those who did not. Endpoints included survival and surgical outcomes. Results: A total of 141 EAC patients received definitive chemoradiation; 83 received induction chemotherapy before chemoradiation. Patients receiving induction chemotherapy were younger (p < 0.01) with slightly lower performance status (p = 0.27) and presented at a more advanced stage (p < 0.001). Median OS was 3.5 years in the induction chemotherapy group compared to 2.2 years (p = 0.10). There was no difference in pathologic complete response (p = 0.81), esophagectomy frequency (p = 0.87), or surgical downstaging between treatment groups (p = 0.84). Conclusions: In this real-world, single-institutional patient cohort investigating induction chemotherapy prior to chemoradiation in EAC, patients receiving induction chemotherapy did well but did not have a statistically significant improvement in survival outcomes or surgical outcomes. This study showed that significant numbers of real-world patients may not receive esophagectomy. Thus, prospective, randomized clinical trials are warranted to better delineate the efficacy and selection of patients for induction chemotherapy when non-operative approaches are favored.

12 October 2026 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
MGMario Gasparri
Mario Gasparri
BBBrent T. Boettcher
Brent T. Boettcher
GGGina Gasparri
Gina Gasparri
SSStefano Schena
Stefano Schena